Use Of Perillyl Alcohol In Organ Transplantation
Utilizing both these immunosuppressive mechanisms, UCLA scientists have determined that perillyl alcohol, a widely-known anti-carcinogen, can be used to reduce graft rejection. By inhibiting activation of the p2l ras oncogene, perillyl alcohol blocks activation of the pathway necessary for lymphocyte proliferation and thus activation. In addition, perillyl alcohol can also reduce the side effects of current anti-rejection agents. By working in a pathway different from its counterparts, perillyl alcohol can be administered alone or in conjunction with other immunosuppressive drugs. Therefore, the doses of these established drugs are decreased and the overall side effects are reduced.These findings suggest that perillyl alcohol may be an important mediator in the field of transplantation surgery by preventing acute and chronic graft rejection. Furthermore, its well-documented anti-carcinogenic and anti-microbial properties may prove to be highly beneficial to immunocompromised transplant patients.
Patent Number: US6133324A
Application Number: US1999305997A
Inventor: Imagawa, David K. | Ming Sing, Si
Priority Date: 7 May 1998
Priority Number: US6133324A
Application Date: 6 May 1999
Publication Date: 17 Oct 2000
IPC Current: A61K0031045 | A61K003813 | A61K004506
US Class: 514729 | 5140166 | 5140205 | 5140211 | 514529 | 514011 | 514019
Assignee Applicant: The Regents of the University of California
Title: Use of perillyl alcohol in organ transplantation
Usefulness: Use of perillyl alcohol in organ transplantation
Summary: To prevent allograft rejection (claimed).
Novelty: Perillyl alcohol and its derivatives are used as immunosuppressive agents in organ transplants to reduce rejection
Disease Diagnostic/Treatment
Other Disease
Tech ID/UC Case 18919/1999-229-0 Related Cases 1999-229-0
USA
